Alzheimer‘s Disease - problem of an aging society
Dementia is one of the fastest growing and most pressing health problems of our time1. Statistics highlight the fact that already mild cognitive impairment (MCI), the prodromal phase of Alzheimer‘s disease, is diagnosed much less frequently than the prevalence would suggest2.
Mild cognitive impairment (MCI: ICD code F06.7) refers to an impairment of cognitive performance that goes beyond what is normal according to the age and education of the person affected but does not cause any significant restrictions in everyday life.
32 million
people living with Alzheimer's disease.
69 million
people living with MCI (prodromal Alzheimer's disease).
315 million
people living with preclinical Alzheimer's disease.
Up to 80 %
of all dementia cases are attributable to Alzheimer's disease.
Do you recognize the difference?
A new approach to early Alzheimer's diagnosis
You can now rely on the digital, non-invasive neotivCare tests for early diagnosis. The app for smartphones and tablets can help you make an initial clinical assessment of people with cognitive complaints without the need for complex test batteries.
Why neotivCare
neotivCare enables an efficient assessment of whether patients with suspected early Alzheimer's disease have a mild cognitive impairment (MCI, ICD code F06.7) of the amnestic type or whether their memory performance is typical for their age.
How the app works
neotivCare contains three types of cognitive tests and is suitable for people over the age of 60 with memory complaints. The results allow a meaningful assessment of suspected MCI and serve as a basis for further differential diagnostics.
Scientifically validated
neotivCare's cognitive tests are the result of years of foundational research and are based on the latest findings in neuroscience and dementia research. They are validated against both diagnostic neuropsychological procedures and biomarkers.
1. Sherzai et al., Am J Lifestyle Med. 2019; 13(5): 451–461. doi.org/10.1177/1559827619843465
2. Gustavsson et al., Alzheimer‘s & Dementia, 2023, 19(2), 658-670. doi.org/10.1002/alz.12694